ArticleIranian journal of biotechnology2025
Identification and Validation of Genes Involved in Energy Metabolism in Polycystic Ovary Syndrome.
Article in Iranian journal of biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metabolic dysregulation plays a critical role in polycystic ovary syndrome (PCOS), yet the involvement of energy metabolism-related genes (ERGs) remains incompletely understood. This study employs integrative bioinformatics and experimental validation to identify key ERGs as potential biomarkers and therapeutic targets in PCOS. Objectives: This study aimed to screen and validate ERGs associated with PCOS by integrating gene expression datasets (GSE34526 and GSE193123) and to explore their molecular mechanisms and therapeutic implications. Materials and Methods: Differentially expressed genes (DEGs) were identified from two GEO datasets and intersected with ERGs from the Reactome database. Functional enrichment, subcellular localization, transcriptional and post-transcriptional regulatory networks, and drug prediction analyses were performed. Clinical validation of candidate biomarkers was conducted using RT-qPCR on granulosa cells from PCOS patients and controls. Results: A total of 159 common DEGs were identified, including three key biomarkers: CD44 (upregulated), HS2ST1, and GPC4 (downregulated). CD44 was localized primarily to the plasma membrane, while HS2ST1 and GPC4 were localized to the Golgi apparatus and nucleus/plasma membrane, respectively. Regulatory network analyses revealed multiple transcription factors, kinases, and miRNAs associated with these biomarkers. Drug prediction identified bisphenol A as a compound linked to all three genes. RT-qPCR confirmed significant upregulation of CD44 in clinical PCOS samples (P<0.05). Conclusion: This study identifies and validates three ERG-associated biomarkers with potential diagnostic and therapeutic utility in PCOS. The integration of bioinformatics and clinical validation underscores the translational relevance of these findings for advancing biotechnological applications in PCOS management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.